Consumer drug advertising remains corporate benefit
managers' favorite culprit in rising prescription drug costs, according to an
Arxcel survey. Forty-five percent cited DTC as the top cause of rising costs,
compared to 36% in 2006 and 30% in 2005. R&D costs placed second, with 24%,
and an aging population ranked third, at 17%.